Related Experiment Video
Updated: Feb 28, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
[High Mobility Group Chromosomal Protein N2 Inhibit Cervical Cancer Transplanted in Nude Mice]
Bin Luo1, Qian-Wen Zhang1, Yu Xu1
1Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu 610041,China.
Objectives:
To study the effect of high mobility group chromosomal protein N2 on inhibiting cervical cancer in nude mice.
Methods:
Model of cervical cancer were established in nude mice. They were randomly divided into 4 groups including negative control group, HMGN2 group, cisplatin group and HMGN2 with cisplatin group. After 4 injections, the tumor size were calculated and tumor tissues were stained by haematoxylin eosin (HE) staining.
Results:
Transplated tumor models were established successfully. The tumor sizes of negative control group [(0.38±0.12) cm³] were significantly lower than those of HMGN2 group [(0.14±0.07)cm³, cisplatin group [(0.11±0.06) cm³] and HMGN2 combined with cisplatin group[(0.11±0.07) cm³]. No differences were detected in HMGN2 group, cisplatin group and HMGN2 with cisplatin group in tumor sizes. The tumor inhibition rates of HMGN2 group, cisplatin group and HMGN2 with cisplatin group were 0.62±0.18, 0.71±0.17 and 0.70±0.18, respectively. The necrosis area were smaller in negative control group than in other three groups by HE staining.
Conclusions:
HMGN2 has a significant inhibitory effect on transplanted cervical cancer in nude mice.
Insights
High mobility group chromosomal protein N2 (HMGN2) effectively inhibits cervical cancer growth in mice. This study demonstrates HMGN2
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cervical cancer remains a significant global health challenge.
- Identifying novel therapeutic targets is crucial for improving treatment outcomes.
Purpose of the Study:
- To investigate the anti-cancer effects of High Mobility Group Chromosomal Protein N2 (HMGN2) on cervical cancer.
- To evaluate HMGN2's efficacy as a potential therapeutic agent in a preclinical model.
Main Methods:
- Cervical cancer models were established in nude mice.
- Mice were divided into four groups: control, HMGN2, cisplatin, and combination therapy.
- Tumor growth and tissue histology (HE staining) were analyzed post-treatment.
Main Results:
- HMGN2 treatment significantly reduced tumor size compared to the control group.
- HMGN2 demonstrated comparable efficacy to cisplatin in inhibiting tumor growth.
- Histological analysis indicated increased necrosis in HMGN2-treated groups.
Conclusions:
- High Mobility Group Chromosomal Protein N2 exhibits significant inhibitory effects on transplanted cervical cancer in vivo.
- HMGN2 represents a promising candidate for cervical cancer therapy, potentially in combination regimens.
More Related Videos
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:23Abnormal Proliferation